Brought to you by 
AstraZeneca pays $560mm, plus potential $590mm in earn-outs, to buy Pearl Therapeutics
26 Aug 2020
Executive Summary
AstraZeneca PLC has paid $560mm up front to buy privately owned Pearl Therapeutics Inc., a company developing inhaled treatments for respiratory diseases. AZ could also pay up to $450mm in development and regulatory earn-outs, plus up to $140mm if specified cumulative sales thresholds are exceeded.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca pays $560mm, plus potential $590mm in earn-outs, to buy Pearl Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice